Organon & Co. (OGN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.22%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.22% | Share-based compensation / revenue. Period ending 2026-06-30. $75.00M ÷ $6.13B × 100 ≈ 1.22% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 6.13B USD | |
| Stock-based compensation | 75.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | 468.00M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.13B | $75.00M | (m) | $468.00M | (m) | 1.22% | (m) | Reported |
| 2026-03-31 | (m) | $6.16B | $72.00M | (m) | $491.00M | (m) | 1.17% | (m) | Reported |
| 2025-12-31 | (m) | $6.22B | $77.00M | (m) | $504.00M | (m) | 1.24% | (m) | Reported |
| 2025-09-30 | (m) | $6.30B | $96.00M | (m) | $515.00M | (m) | 1.52% | (m) | Reported |
| 2025-06-30 | (m) | $6.28B | $97.00M | (m) | $513.00M | (m) | 1.54% | (m) | Reported |
| 2025-03-31 | (m) | $6.29B | $103.00M | (m) | $513.00M | (m) | 1.64% | (m) | Reported |
| 2024-12-31 | (m) | $6.40B | $105.00M | (m) | $520.00M | (m) | 1.64% | (m) | Reported |
| 2024-09-30 | (m) | $6.41B | $106.00M | (m) | $517.00M | (m) | 1.65% | (m) | Reported |
| 2024-06-30 | (m) | $6.35B | $108.00M | (m) | $525.00M | (m) | 1.70% | (m) | Reported |
| 2024-03-31 | (m) | $6.35B | $105.00M | (m) | $526.00M | (m) | 1.65% | (m) | Reported |
| 2023-12-31 | (m) | $6.26B | $101.00M | (m) | $527.00M | (m) | 1.61% | (m) | Reported |
| 2023-09-30 | (m) | $6.15B | $97.00M | (m) | $517.00M | (m) | 1.58% | (m) | Reported |
| 2023-06-30 | (m) | $6.17B | $88.00M | (m) | $491.00M | (m) | 1.43% | (m) | Reported |
| 2023-03-31 | (m) | $6.14B | $82.00M | (m) | $457.00M | (m) | 1.33% | (m) | Reported |
| 2022-12-31 | (m) | $6.17B | $75.00M | (m) | $422.00M | (m) | 1.21% | (m) | Reported |
| 2022-09-30 | (m) | $6.29B | $67.00M | (m) | $401.00M | (m) | 1.06% | (m) | Reported |
| 2022-06-30 | (m) | $6.36B | $64.00M | (m) | $391.00M | (m) | 1.01% | (m) | Reported |
| 2022-03-31 | $472.00M | $6.37B | $63.00M | (m) | $355.00M | 7.42% | 0.99% | (m) | Reported |
| 2021-12-31 | $443.00M | $6.30B | $59.00M | (m) | $258.00M | 7.03% | 0.94% | (m) | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $210.00M | $6.53B | $40.00M | (m) | $0.00 | 3.21% | 0.61% | (m) | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $220.00M | $7.78B | $41.00M | (m) | $0.00 | 2.83% | 0.53% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |